# Testing the Addition of M6620 (VX-970, Berzosertib) to Usual Chemotherapy and Radiation for Head and Neck Cancer

> **NCT02567422** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **National Cancer Institute (NCI)** · enrollment: 43 (actual)

## Conditions studied

- Head and Neck Carcinoma of Unknown Primary
- Head and Neck Squamous Cell Carcinoma
- Stage III Hypopharyngeal Squamous Cell Carcinoma AJCC v7
- Stage III Laryngeal Squamous Cell Carcinoma AJCC v6 and v7
- Stage III Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7
- Stage III Oropharyngeal Squamous Cell Carcinoma AJCC v7
- Stage III Sinonasal Squamous Cell Carcinoma AJCC v6 and v7
- Stage IV Hypopharyngeal Squamous Cell Carcinoma AJCC v7
- Stage IV Laryngeal Squamous Cell Carcinoma AJCC v7
- Stage IV Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7
- Stage IV Oropharyngeal Squamous Cell Carcinoma AJCC v7
- Stage IV Sinonasal Squamous Cell Carcinoma AJCC v7

## Interventions

- **DRUG:** Berzosertib
- **DRUG:** Cisplatin
- **PROCEDURE:** Computed Tomography
- **OTHER:** Laboratory Biomarker Analysis
- **PROCEDURE:** Magnetic Resonance Imaging
- **PROCEDURE:** Positron Emission Tomography
- **RADIATION:** Radiation Therapy

## Key facts

- **NCT ID:** NCT02567422
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2017-04-17
- **Primary completion:** 2023-12-31
- **Final completion:** 2026-05-14
- **Target enrollment:** 43 (ACTUAL)
- **Last updated:** 2025-12-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02567422

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02567422, "Testing the Addition of M6620 (VX-970, Berzosertib) to Usual Chemotherapy and Radiation for Head and Neck Cancer". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT02567422. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*